Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PTGES | O14684 | 6/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4757946 | 0.81 | HTT (0.37) | BRD4LMNAPPARGPTGESMEN1 | |
| SCHEMBL4755797 | 0.81 | SMN1; SMN2 (0.49) | ATMSMN1; SMN2LMNATSHRMEN1 | |
| SCHEMBL3866782 | 0.81 | TLR7 (0.43) | SMN1; SMN2BRD4LMNATSHRPPARG | |
| SCHEMBL4757052 | 0.81 | HTT (0.33) | SMN1; SMN2BRD4LMNAPPARGPTGES | |
| SCHEMBL4757047 | 0.80 | PPARG (0.33) | SMN1; SMN2LMNATSHRPPARGPTGES | |
| SCHEMBL5415670 | 0.80 | PPARG (0.39) | ATMSMN1; SMN2LMNATSHRPPARG | |
| SCHEMBL3169725 | 0.79 | TLR7 (0.43) | BRD4TSHRPPARGMEN1KMT2A | |
| SCHEMBL3863839 | 0.79 | TLR7 (0.46) | BRD4PPARGTLR8TLR7 | |
| SCHEMBL29883069 | 0.78 | ADORA3 (0.40) | SMN1; SMN2TLR8TLR7ADORA3 | |
| SCHEMBL22323653 | 0.78 | ADORA3 (0.40) | SMN1; SMN2TLR8TLR7ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1605943-A4 | 1-AMINO 1H-IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2008-01-16 | — | — | EP | disclosed |
| US-7163947-B2 | 1-Amino 1H-imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-01-16 | — | — | US | disclosed |
| WO-2006028451-A1 | 1-AMINO 1-H-IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-03-16 | — | — | WO | disclosed |
| EP-1605943-A2 | 1-AMINO 1H-IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20050054640-A1 | 1-Amino 1H-imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2005-03-10 | — | — | US | disclosed |
| WO-2004080398-A2 | 1-AMINO 1H-IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2004-09-23 | — | — | WO | disclosed |
| US-20040176367-A1 | 1-Amino 1H-imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176367-A1 | 1-Amino 1H-imidazoquinolines | IL2, IFNG, IL4I1 | ATM 3198/4885SMN1; SMN2 2646/4885BRD4 178/4885 |
| US-20050054640-A1 | 1-Amino 1H-imidazoquinolines | IL2, IFNG, IL4I1 | ATM 3198/4885SMN1; SMN2 2646/4885BRD4 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.